Recent studies have shown that the upregulation of SEMA7A expression is significantly associated with multiple sclerosis (18), systemic sclerosis–related interstitial lung disease (19), rheumatoid arthritis (20), airway inflammation (21), colitis (22), systemic lupus erythematosus (23), and melanoma and other cancers (24). Here, SEMA7A is linked to melanoma.